Press conference involving POSC and major company

Following up on the rumors we have been chasing  for two weeks, it appears that staffers at Positron Corporation  (OTCBB:POSC) have been busy making arrangements for a soon to be  announced press conference.

Yesterday, prices took a hit after a blogger made false and  defamatory accusations against not only BioMedReports, but the company  as well. This is the second time that the blogger has attacked  BioMedReports's and owners of this website intend to take swift and  complete legal action against the owner/author of that web site. Thus  far, after multiple requests, the author of the website has refused to  provide us with his legal contact information so that our legal  department can commence those actions.

The fact remains that POSC is an established company that has been in  business for over a quarter of a century and that a positive  announcement- apparently worthy of a press conference- will be made  public in the coming days. Speculation continues that a multi-billion  dollar company trading on the NYSE at over $50 per share has taken an  interest in the company.

Furthermore, sources at the company tell BioMedReports that pending  orders for their FDA approved, Frost and Sullivan award winning imaging  system run at least "over one hundred deep."

As we told subscribers two days ago, we fully expect the stock price  to see substantial  gains (beyond the initial 43% gains seen immediately  after our trade alert) as it now appears that the company had  positioned itself to be the clear leader in  the five billion dollar  molecular imaging market. Positron's PET  (Positron Emission Tomography)  scanner, known as the “Attrius”, has  robust cardiac specific imaging  software and, more importantly, is the  only "PET" imaging device in the  entire industry (see related story).

In a letter to   shareholders last month, the chairman of the board for the company  informed investors that "Positron has  several immediate opportunities  with some of the largest companies in  the nuclear medicine industry.  Any combination of success with these  opportunities will have a  tremendous positive present and future impact  on Positron."

It is clear that a positive development worthy of a full press  conference (rumored arrangements place it at the Nasdaq MarketSite in  New York City) may be officially announced as early as Monday.

If true, naked shorters who took negative positions in the stock will  not only have to cover, they will help push the stock price much higher  by doing so.

Developing...

After  alerting members to Positron Corporation (OTC:POSC), the stock roared  from $.06 to a fifty-two week high of $.30. Shortly after that, we advised our readers and subscribers that they  should consider selling their positions in POSC before the scheduled  press conference, fearing that the event could become a "buy on rumor  sell on news" event.

We've come back from vacation to an email box full of both love and  hate mail, thus the title of today's article.

Apparently, our advice to "sell" prior to the press event did not go  over well with many of the longs who felt that we were sending mixed  messages about the stock, but after carefully considering what many day  traders do with these "forward looking" types of stock plays, our  editors felt strongly that we should advise our readers despite the  potential for back lash.

As it turned out, things got even uglier than any of us expected when  the company decided not to announce their highly anticipated  partnership details to an audience of reporters in attendance at New  York's Nasdaq Marketsite. Most of the reporters covering the event  didn't even blink, but the tens of thousands of investors who were  following the conference via webcast immediately responded by dumping  their shares. What resulted was a wave of attacks and false accusations  about BMR promoting and/or pumping and dumping the stock. Those who  followed the advice and erred on the side of caution won while those who  decided to gamble more speculatively paid a price.

At the end of the day, the facts still remain: POSC is a solid  company that has been around for over 27 years. The CEO may need more  media relations training given his very rough delivery at the podium,  but  reporters at the event (none of whom even asked about the  partnership details that investors were craving) seemed to take the most  interest in management's announcement that POSC anticipates generating  over $200 million in revenue within 18 months and over a billion in  revenue within 4 to 5 years. This is a stock that many of us have jumped  back in on and is still available for mere pennies per share.

Even though they fully intended to when the news conference was  scheduled, POSC could not announce the name of the key partnership they  wanted to reveal at the press conference for a number of reasons. As we  understand it, there are at least one contractual and several strategic  partnerships in the works or even already in place. As many disappointed  and angry investors called and cried for full disclosure under threats  of lawsuits, the company followed up with a cryptic press release about  the matter in the days following the conference. Although no one at the  company can go on record publicly for the same reasons we mentioned, we  have confirmed to the best of our abilities and based on candid  interviews with multiple sources, that Positron has partnered with  Covidien (NYSE:COV). In addition, our sources tell us that they are also  in the process of aligning with other big board companies for some very  important strategic partnerships on the pharmaceutical side of the  business. Furthermore, it's worth considering that any one of these  strategic partners may choose to take a position in or even outright buy  the company; especially once the new network of automated imaging drug  dispensing machines is set up.

BMR was told that at one point, one of Positron's newest allies had  apparently gone so far as to "threaten them" before deciding that  joining  forces might be a better way to respond to their innovative  nuclear medicine's dispensing and distribution technology. The bonding  experience with that company is still shaky, but much more friendly now  according to those familiar with the situation and it definitely played  into why the company decided against the public revelations.

If  one looks at POSC and it's FDA approved PET Scan imaging technologies,  the back orders for systems, and the shift not only in the marketplace,  but also the reimbursement as well as medical and technical needs of the  cardio and oncology imaging space, it's clear to see that the company  is not only undervalued, but vastly undervalued. Look up IMGG and you'll  find a company that traded at close to $2 per share this year based on  only "half the promise" that POSC offers today. That company has  submitted for FDA approvals several times and still have no clearance,  yet they still trade today at nearly fifty cents per share.

Is  the company trading higher than it was when we first covered it?  Absolutely, and it is difficult to argue that the share price will not  continue to rise as future revenues, orders and developments are  announced. Do we continue to see it as a multi-bagger? Of course we do.  Especially given the fact that the entire space they deal in is changing  and that they are positioned without a single competitor as the leading  company within that space.

Positron  Corporation (OTCBB:POSC), a leader in molecular imaging and solutions  specializing in the field of Nuclear Cardiology has just released a  report over the news wires highlighting some of the company's key points  and developments.

The stock has been seeing quite a bit of accumulation since shares  broke the $.10 support level a few days ago and Thursday, shares closed  up 11.6% at $.125. We believe the stock will climb higher pending  announcements and long awaited official revelation of a key relationship  or two with big-cap firms in the biotech imaging space. Those  relationships and developments, as they are announced, may signal what  investors have been waiting for: the validation and start of next level  of commercialization and deployment activities surrounding the company's  Molecular Imaging Devices and Radiopharmaceutical Products.

Here is a marked up technical analysis chart of the company: